The Pew Charitable Trusts
In March, nearly 40 individuals from across the country will meet with their legislators to urge Congress to take bipartisan action to prioritize the battle against antibiotic resistance: a looming global health threat that threatens the future of modern medicine. As part of The Pew Charitable Trusts’ Stand Up to Superbugs initiative, this year’s ambassadors include health care professionals, public health officials, scientists, farmers and ranchers, veterinarians, superbug survivors, and people who have lost loved ones to an antibiotic-resistant infection. They will meet virtually with federal agency leaders and members of Congress to share their superbug stories and expertise, and urge increased commitment and momentum to preserve the effectiveness of existing antibiotics and develop urgently needed new ones.
E-Mail
Targeted radiation is often used to study and treat diverse cancer types. A multidisciplinary research team based at the University of Chicago Medicine has recently focused on a type of cell that releases a protein that enhances resistance to cancer therapies and promotes tumor progression.
The study focused on Ter cells, which are extra medullary erythroid precursers that secrete the neuropeptide artemin. In the study, published February 24, 2020, in
Science Translational Medicine, the researchers showed that local tumor radiotherapy, systemic immunotherapy or the combination of both treatments were able to deplete Ter cells in the spleen, reduce artemin production and limit tumor progression both in the locally irradiated tumors as well as outside the radiation fields.
Study: Depleted uranium from tanks, ammo not tied to Gulf War syndrome bigrapidsnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bigrapidsnews.com Daily Mail and Mail on Sunday newspapers.
Meth has devastated the gay community for decades. A new treatment offers hope. Benjamin Ryan Do you want to be a 50-year-old meth addict?
For Roger, the enormity of what he had lost during his nearly two decades of off-and-on methamphetamine use and what more he had to lose hit home hard when a man he was dating asked him that question.
Roger, who was 47 at the time, had already suffered a major ischemic stroke thanks to meth, the powerfully addictive stimulant that had long since taken over his life.
So when Roger, who is from Dallas and asked that his last name not be published for fear that meth s stigma could hurt his career, heard that a study was looking for people like him to test a treatment for meth use disorder, he jumped at the chance.